Illumina has picked Jacob Thaysen as its new CEO, roughly three months after the company parted ways with Francis deSouza following a fight with an activist investor and amid struggling fortunes as it wrestles with antitrust authorities.
The appointment of Thaysen, most recently the president of Agilent Technologies’ life sciences and applied markets group, signals an attempt by the genetic testing company to put a leader with deep roots in the advanced diagnostics business at the helm. Illumina’s announcement also extensively highlighted Thaysen’s track record of financial results at Agilent, in particular noting how he “drove the division’s revenue and significantly improved its operating profit.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.